Triple-Negative Breast Cancer: Lucy's Survivor Story
This breast cancer diagnosis at a glance
- Biomarkers
- BRCA1 mutation; triple-negative breast cancer
- Sex
- Female
- Treatment
- fertility preservation, ovarian suppression, chemotherapy, a clinical trial, surgery, radiation and reconstruction
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- Egg freezing was done before treatment
- Zoladex injections during chemotherapy put her into temporary medical menopause
- Clinical trial used carboplatin every 3 weeks, weekly paclitaxel, and daily olaparib tablets for 4 cycles / intended 12 weeks, with a platelet-related break
- EC chemotherapy followed for 3 cycles every 3 weeks / 9 weeks
- After chemotherapy, she received an all-clear/cancer-free result on June 17
- Because of BRCA1 mutation and node involvement, she chose double mastectomy
- Left side stayed flat because radiation delayed reconstruction; right-side implant was placed
- Ongoing care included oncology reviews every 3-4 months and plastic-surgery planning.
What happened, in summary
Lucy E. was diagnosed with grade 3 triple-negative breast cancer 3 days after her 24th birthday. She had found a breast lump and pushed for biopsy even after being told it was likely fibrous tissue. She already knew she carried a BRCA1 mutation, which made the diagnosis and future family planning more complicated. Treatment moved quickly after the October 13 diagnosis. Before chemotherapy, Lucy completed egg freezing and discussed future embryo testing to avoid passing on the BRCA gene. She also received Zoladex injections during chemotherapy to help protect ovarian function by putting her into temporary medical menopause. Lucy joined a clinical trial. Her main chemotherapy course was carboplatin every 3 weeks plus weekly paclitaxel, with daily olaparib tablets as part of the trial. That phase was planned for 4 cycles / 12 weeks, although low platelets caused a break. She then received EC chemotherapy every 3 weeks for 3 cycles, lasting 9 weeks. Hair loss, fatigue, and treatment side effects were emotionally difficult. On June 17, after chemotherapy, she was told she was all-clear and cancer-free. Surgery still followed. Because of BRCA1 and node involvement, she chose a double mastectomy. Radiotherapy meant the left side could not be reconstructed immediately, so she stayed flat on the left and had a right implant, with DIEP reconstruction planning later. As of January 2023, Lucy was cancer-free and continuing close oncology reviews every 3-4 months.
Where this story comes from
This is a lay summary of an account first published by The Patient Story. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer